| Literature DB >> 26315525 |
Jin He1, Nita Ahuja2.
Abstract
Cancers are characterized by complex tumor heterogeneity driven by subclones with differential genotypes and phenotypes, which then drives cancer behavior. As genomic strategies become feasible on smaller samples such as biopsies, coupled with decreasing costs of these approaches, clinicians will increasingly use genomic information to drive therapeutic decision making. Early applications of such personalized approaches are discussed. Genetic testing of high-risk family members may identify patients with germline mutations who can have prophylactic surgeries as a cancer prevention strategy. This article discusses examples of successful targeted therapy. Clinical trials need to incorporate genetic testing to stratify patients into different groups.Entities:
Keywords: Biomarkers; Next-generation sequencing; Targeted therapy; Tumor heterogeneity
Mesh:
Substances:
Year: 2015 PMID: 26315525 DOI: 10.1016/j.suc.2015.05.002
Source DB: PubMed Journal: Surg Clin North Am ISSN: 0039-6109 Impact factor: 2.741